Gene therapy for hemophilia B mice with scAAV8-LP1-hFIX

doi:10.1007/s11684-016-0438-y

Front. Med.

2016, Vol. 10

Issue (2) : 212-218 https://doi.org/10.1007/s11684-016-0438-y

RESEARCH ARTICLE

Gene therapy for hemophilia B mice with scAAV8-LP1-hFIX

Wei Lu¹,Qingzhang Zhou^2,³,Hao Yang¹,Hao Wang¹,Yexing Gu¹,Qi Shen¹,Jinglun Xue¹,Xiaoyan Dong^2,^*(

),Jinzhong Chen^1,^*(

)

¹. State Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai 200433, China
². Beijing Five Plus Molecular Medicine Institute, Beijing 100176, China
³. College of Life Sciences, Jilin University, Changchun 130012, China

Download: PDF(1384 KB) HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Abstract

Hemophilia B is a hemorrhagic disease caused by the deficiency of clotting factor IX (FIX). Gene therapy might be the ultimate strategy for the disease. However, two main problems that should be solved in gene therapy for hemophilia B are immunity and safety. Self-complementary adeno-associated virus serotype 8 (scAAV8), a non-human primate AAV featuring low immunogenicity and high transfection efficiency in liver cells, might be a potential vector for hemophilia B gene therapy. A strong liver-specific promoter-1 (LP1) was inserted and mutant human FIX Arg338Ala was introduced into plasmid scAAV8-LP1 to develop an optimized AAV8 vector that expresses human clotting factor FIX (hFIX). The efficiency of scAAV8-LP1-hFIX administered through normal systemic injection or hydrodynamic injection was compared. A high expression was achieved using hydrodynamic injection, and the peak hFIX expression levels in the 5×10¹¹ and 1×10¹¹virus genome (vg) cohorts were 31.94% and 25.02% of normal level, respectively, at 60 days post-injection. From the perspective of long-term (200 days) expression, both injection methods presented promising results with the concentration value maintained above 4% of normal plasma. The results were further verified by enzyme-linked immunosorbent assay and activated partial thromboplastin time. Our study provides a potential gene therapy method for hemophilia B.

Keywords hemophilia B AAV8 hFIX gene therapy

Corresponding Author(s): Xiaoyan Dong,Jinzhong Chen

Just Accepted Date: 16 March 2016 Online First Date: 06 April 2016 Issue Date: 27 May 2016

Cite this article:

Wei Lu,Qingzhang Zhou,Hao Yang, et al. Gene therapy for hemophilia B mice with scAAV8-LP1-hFIX[J]. Front. Med., 2016, 10(2): 212-218.

URL:

https://academic.hep.com.cn/fmd/EN/10.1007/s11684-016-0438-y
https://academic.hep.com.cn/fmd/EN/Y2016/V10/I2/212

Fig.1 Southern blot analysis of viral genomes of scAAV8-LP1-hFIX vectors. Genome of scAAV8-LP1-hFIX was characterized by Southern blot in lane1, and the 4900 nt ssDNA marker was in lane2.

Fig.2 Expression of hFIX after the injection of rscAAV8-LP1-FIX in hemophilia B mice (n = 4 per cohort). Plasma human FIX (hFIX) level (mean±SEM) measured by enzyme-linked immunosorbent assay (ELISA) at indicated time points (7, 14, 21, 30, 60, 90, 150, and 200 days post-injection) following the injection of rscAAV8-LP1-FIX with two injection methods (n = 4 in each cohort). (FH) 5 × 10¹¹vg by hydrodynamic injection; (FM) 1 × 10¹¹vg by hydrodynamic injection; (BH) 5 × 10¹¹vg by normal system injection; (BM) 1 × 10¹¹vg by normal system injection; (Control) PBS.

Fig.3 hFIX antibody level after the injection of rscAAV8-LP1-FIX in hemophilia B mice. Plasma hFIX antibody level measured by ELISA at indicated time points (7, 14, 21, 30, 60, 90, 150, and 200 days post-injection) following the hydrodynamic injection of rscAAV8-LP1-FIX. (FH) 5 × 10¹¹vg by hydrodynamic injection; (FM) 1 × 10¹¹vg by hydrodynamic injection; (BH) 5 × 10¹¹vg by normal system injection; (BM) 1 × 10¹¹vg by normal system injection; (Control) PBS.

Fig.4 Clotting time of all the experimental and wild-type cohorts at 30 days after injection. The tail was cut 1 cm, and filter paper was used to touch the wound on the tail every few seconds until no blood was shown on the filter paper. (FH) 5 × 10¹¹vg by hydrodynamic injection; (FM) 1 × 10¹¹vg by hydrodynamic injection; (BH) 5 × 10¹¹vg by normal system injection; (BM) 1 × 10¹¹vg by normal system injection; (control) PBS; (NA) hemophilia B mice; (WT) wild type.

Fig.5 Immunohistochemistry of hFIX-expressing hepatocytes in hemophilia B mice that received 5 × 10¹¹vg of rscAAV8-LP1-FIX vector and PBS 100 days post-injection. Magnification of all images is 100×. (A) Paraffin section from the liver of PBS treated mouse; (B) paraffin section from the liver of rscAAV8-LP1-FIX-treated mouse.

Fig.6 Histological examination of liver tissue that received 5 × 10¹¹vg of the rscAAV8-LP1-FIX vector and PBS by hydrodynamic injection. Animals following the hydrodynamic injection of 5 × 10¹¹vg and PBS were sacrificed on days 1 and 100. Magnification of all images is 100×. (A and C) Tissue from liver of rscAAV8-LP1-FIX-treated mouse; (A) 1 day; (C) 100 days. (B and D) Tissue from liver of PBS-treated mouse; (B) 1 day; (D) 100 days.

1	Nathwani AC, Tuddenham EG. Epidemiology of coagulation disorders. Baillieres Clin Haematol 1992; 5(2): 383–439 https://doi.org/10.1016/S0950-3536(11)80025-9 pmid: 1511181
2	Löfqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients—a long-term follow-up. J Intern Med 1997; 241(5): 395–400 https://doi.org/10.1046/j.1365-2796.1997.130135000.x pmid: 9183307
3	Ljung RC. Can haemophilic arthropathy be prevented? Br J Haematol 1998; 101(2): 215–219 https://doi.org/10.1046/j.1365-2141.1998.00707.x pmid: 9609513
4	Miller AD. Human gene therapy comes of age. Nature 1992; 357(6378): 455–460 https://doi.org/10.1038/357455a0 pmid: 1608446
5	Crystal RG, McElvaney NG, Rosenfeld MA, Chu CS, Mastrangeli A, Hay JG, Brody SL, Jaffe HA, Eissa NT, Danel C. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet 1994; 8(1): 42–51 https://doi.org/10.1038/ng0994-42 pmid: 7527271
6	Flotte T, Carter B, Conrad C, Guggino W, Reynolds T, Rosenstein B, Taylor G, Walden S, Wetzel R. A phase I study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease. Hum Gene Ther 1996; 7(9): 1145–1159 https://doi.org/10.1089/hum.1996.7.9-1145 pmid: 8773517
7	Levine BL, Humeau LM, Boyer J, MacGregor RR, Rebello T, Lu X, Binder GK, Slepushkin V, Lemiale F, Mascola JR, Bushman FD, Dropulic B, June CH. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci USA 2006; 103(46): 17372–17377 https://doi.org/10.1073/pnas.0608138103 pmid: 17090675
8	Qiu X, Lu D, Zhou J, Wang J, Yang J, Meng P, Hsueh JL. Implantation of autologous skin fibroblast genetically modified to secrete clotting factor IX partially corrects the hemorrhagic tendencies in two hemophilia B patients. Chin Med J (Engl) 1996; 109(11): 832–839 pmid: 9275366
9	Tsui LV, Kelly M, Zayek N, Rojas V, Ho K, Ge Y, Moskalenko M, Mondesire J, Davis J, Roey MV, Dull T, McArthur JG. Production of human clotting factor IX without toxicity in mice after vascular delivery of a lentiviral vector. Nat Biotechnol 2002; 20(1): 53–57 https://doi.org/10.1038/nbt0102-53 pmid: 11753362
10	Brown BD, Cantore A, Annoni A, Sergi LS, Lombardo A, Della Valle P, D’Angelo A, Naldini L. A microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice. Blood 2007; 110(13): 4144–4152 https://doi.org/10.1182/blood-2007-03-078493 pmid: 17726165
11	Ehrhardt A, Kay MA. A new adenoviral helper-dependent vector results in long-term therapeutic levels of human coagulation factor IX at low doses in vivo. Blood 2002; 99(11): 3923–3930 https://doi.org/10.1182/blood.V99.11.3923 pmid: 12010790
12	Ehrhardt A, Xu H, Dillow AM, Bellinger DA, Nichols TC, Kay MA. A gene-deleted adenoviral vector results in phenotypic correction of canine hemophilia B without liver toxicity or thrombocytopenia. Blood 2003; 102(7): 2403–2411 https://doi.org/10.1182/blood-2003-01-0314 pmid: 12805062
13	Cooper M, Nayak S, Hoffman BE, Terhorst C, Cao O, Herzog RW. Improved induction of immune tolerance to factor IX by hepatic AAV-8 gene transfer. Hum Gene Ther 2009; 20(7): 767–776 https://doi.org/10.1089/hum.2008.161 pmid: 19309290
14	Allay JA, Sleep S, Long S, Tillman DM, Clark R, Carney G, Fagone P, McIntosh JH, Nienhuis AW, Davidoff AM, Nathwani AC, Gray JT. Good manufacturing practice production of self-complementary serotype 8 adeno-associated viral vector for a hemophilia B clinical trial. Hum Gene Ther2011; 22(5):595-604 https://doi.org/10.1038/mt.2010.274 pmid: 21245849
15	Nathwani AC, Rosales C, McIntosh J, Rastegarlari G, Nathwani D, Raj D, Nawathe S, Waddington SN, Bronson R, Jackson S, Donahue RE, High KA, Mingozzi F, Ng CY, Zhou J, Spence Y, McCarville MB, Valentine M, Allay J, Coleman J, Sleep S, Gray JT, Nienhuis AW, Davidoff AM. Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. Mol Ther 2011; 19(5): 876–885 https://doi.org/10.1038/mt.2010.274 pmid: 21245849
16	Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC, Chowdary P, Riddell A, Pie AJ, Harrington C, O’Beirne J, Smith K, Pasi J, Glader B, Rustagi P, Ng CY, Kay MA, Zhou J, Spence Y, Morton CL, Allay J, Coleman J, Sleep S, Cunningham JM, Srivastava D, Basner-Tschakarjan E, Mingozzi F, High KA, Gray JT, Reiss UM, Nienhuis AW, Davidoff AM. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011; 365(25): 2357–2365 https://doi.org/10.1056/NEJMoa1108046 pmid: 22149959
17	Nathwani AC, Reiss UM, Tuddenham EG, Rosales C, Chowdary P, McIntosh J, Della Peruta M, Lheriteau E, Patel N, Raj D, Riddell A, Pie J, Rangarajan S, Bevan D, Recht M, Shen YM, Halka KG, Basner-Tschakarjan E, Mingozzi F, High KA, Allay J, Kay MA, Ng CY, Zhou J, Cancio M, Morton CL, Gray JT, Srivastava D, Nienhuis AW, Davidoff AM. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 2014; 371(21): 1994–2004 https://doi.org/10.1056/NEJMoa1407309 pmid: 25409372
18	Chang J, Jin J, Lollar P, Bode W, Brandstetter H, Hamaguchi N, Straight DL, Stafford DW. Changing residue 338 in human factor IX from arginine to alanine causes an increase in catalytic activity. J Biol Chem 1998; 273(20): 12089–12094 https://doi.org/10.1074/jbc.273.20.12089 pmid: 9575152
19	Haberman RA, Kroner-Lux G, McCown TJ, Samulski RJ. Current protocols in neuroscience. New York, N.Y.: John Wiley and Sons, 1999
20	Lin HF, Maeda N, Smithies O, Straight DL, Stafford DW. A coagulation factor IX-deficient mouse model for human hemophilia B. Blood 1997; 90(10): 3962–3966 pmid: 9354664
21	Zhang G, Budker V, Wolff JA. High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum Gene Ther 1999; 10(10): 1735–1737 https://doi.org/10.1089/10430349950017734 pmid: 10428218
22	Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 1999; 6(7): 1258–1266 https://doi.org/10.1038/sj.gt.3300947 pmid: 10455434
23	Kim HS, Kim JC, Lee YK, Kim JS, Park YS. Hepatic control elements promote long-term expression of human coagulation factor IX gene in hydrodynamically transfected mice. J Gene Med 2011; 13(7-8): 365–372 https://doi.org/10.1002/jgm.1583 pmid: 21710610
24	Herzog RW, Hagstrom JN, Kung SH, Tai SJ, Wilson JM, Fisher KJ, High KA. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci USA 1997; 94(11): 5804–5809 https://doi.org/10.1073/pnas.94.11.5804 pmid: 9159155
25	Miao CH, Thompson AR, Loeb K, Ye X. Long-term and therapeutic-level hepatic gene expression of human factor IX after naked plasmid transfer in vivo. Mol Ther 2001; 3(6): 947–957 https://doi.org/10.1006/mthe.2001.0333 pmid: 11407909
26	Xu ZX, Chen JZ, Yue YB, Zhang JQ, Li ZH, Feng DM, Ruan ZC, Tian L, Xue JL, Wang QJ, Jia W. A 16-bp RBE element mediated Rep-dependent site-specific integration in AAVS1 transgenic mice for expression of hFIX. Gene Ther 2009; 16(5): 589–595 https://doi.org/10.1038/gt.2009.9 pmid: 19242526
27	Xu Z, Ye J, Zhang A, Xie L, Shen Q, Xue J, Chen J. Gene therapy for hemophilia B with liver-specific element mediated by Rep-RBE site-specific integration system. J Cardiovasc Pharmacol 2015; 65(2): 153–159 https://doi.org/10.1097/FJC.0000000000000172 pmid: 25295466
28	Graham T, McIntosh J, Work LM, Nathwani A, Baker AH. Performance of AAV8 vectors expressing human factor IX from a hepatic-selective promoter following intravenous injection into rats. Genet Vaccines Ther 2008; 6(1): 9 https://doi.org/10.1186/1479-0556-6-9 pmid: 18312698

[1]	Yanlin Zhao,Xiao Zhong,Xiaohong Ou,Huawei Cai,Xiaoai Wu,Rui Huang. Cotransfecting norepinephrine transporter and vesicular monoamine transporter 2 genes for increased retention of metaiodobenzylguanidine labeled with iodine 131 in malignant hepatocarcinoma cells[J]. Front. Med., 2017, 11(1): 120-128.
[2]	Ru Zhang,Qiang Wang,Lin Zhang,Saijuan Chen. Optimized human factor IX expression cassettes for hepatic-directed gene therapy of hemophilia B[J]. Front. Med., 2015, 9(1): 90-99.
[3]	Chuanfeng Wu, Cynthia E. Dunbar. Stem cell gene therapy: the risks of insertional mutagenesis and approaches to minimize genotoxicity[J]. Front Med, 2011, 5(4): 356-371.
[4]	Jian XIN BM, Ze-Feng XIA MD, Kai-Xiong TAO MD, Kai-Lin CAI PhD, Gao-Xiong HAN MD, Xiao-Ming SHUAI MD, Ji-Liang WANG MD, Han-Song DU MD, Guo-Bin WANG PhD, Yan LUO MM, . Development of a magnetite-gene complex for gene transfection[J]. Front. Med., 2010, 4(2): 241-246.
[5]	Xudong YU MM, Zengwu SHAO MD, Liming XIONG MD, Weiwei XU MM, Hezhong WANG MM, Huifa XU MM, . Adenovirus-mediated tissue inhibitor of metalloproteinase-3 gene transfection inhibits rabbit intervertebral disc degeneration in vivo[J]. Front. Med., 2009, 3(4): 415-420.
[6]	Youguo HAO, Min ZHANG, Jinzhi XU, Bitao BU, Jiajun WEI. Construction of lentiviral vector carrying Rab9 gene and its expression in mouse brain[J]. Front Med Chin, 2009, 3(2): 141-147.
[7]	XIA Xi, WANG Beibei, CAO Li, CHEN Gang, WU Peng, LU Yunping, ZHOU Jianfeng, MA Ding. Investigation of gene therapy of denovirus in immune suppression[J]. Front. Med., 2008, 2(4): 386-390.
[8]	XIONG Ying, GUO Wen, LI Ting, LI Ke. Influence of Survivin-targeted siRNA on the biological features of colorectal carcinoma cells[J]. Front. Med., 2007, 1(3): 304-307.
[9]	TIAN Yongji, LI Guilin, GAO Jun, WANG Renzhi, KONG Yanguo, ZHANG Zhenxing, LI Shifang, TIAN Shiqiang, DOU Wanchen, ZHANG Bo. Construction of 6HRE-GFAP-Baxα system specific for glioma gene therapy[J]. Front. Med., 2007, 1(1): 49-53.

Viewed

Full text

Abstract

Cited

Shared

Discussed